Brief: Synaptogenix And Cleveland Clinic To Submit IND Application To FDA For Clinical Trial Of Bryostatin-1 In Multiple Sclerosis

TAO Synergies

19/07/2023 14:10

July 19 (Reuters) - Synaptogenix Inc  SNPX.O :
    * SYNAPTOGENIX AND CLEVELAND CLINIC TO SUBMIT
INVESTIGATIONAL NEW
DRUG (IND) APPLICATION TO FDA FOR CLINICAL TRIAL OF BRYOSTATIN-1
IN MULTIPLE SCLEROSIS


Further company coverage:  SNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))